CAR-T cell therapy is now licensed to treat some relapsed leukaemias or lymphomas. It is now also in development to treat “solid” tumours, including cancers and sarcomas.
There has been rapid progress in improving CAR-T cell therapy for cancers in general. Round the world, thousands of patients have now received CAR-T cell therapies.
Clinical trials are now expanding further – offering patients with different cancers that no longer respond to conventional therapy chances to benefit from CAR-T cell therapy.
Recent studies show the benefit of CAR-T cell therapy for cancers in and around the lungs, including mesothelioma, and for childhood cancers, neuroblastoma and osteosarcoma.
Safety of CAR-T therapy has also improved. New treatments are available to reduce toxicity in patients’ lungs and nervous systems, if symptoms of these start to occur.
It is uncommon now for patients to spend long in hospital after CAR-T cell therapy. Within a few weeks after CAR-T cell therapy most initial toxicity has already subsided. The general health of most patients is good within a month or two after therapy.